L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix AI appoints Dr. Pedro Romero as Chief Medical & Scientific Officer
LAUSANNE, SWITZERLAND – Novigenix AI, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix AI. In his new role
Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood RNA biomarkers, and mapping